Abstract
We wanted to investigate whether urine albumin/creatinine ratio (UACR) and left ventricular (LV) mass, both being associated with diabetes and increased blood pressure, predicted cardiovascular events in patients with hypertension independently. After 2 weeks of placebo treatment, clinical, laboratory and echocardiographic variables were assessed in 960 hypertensive patients from the LIFE Echo substudy with electrocardiographic LV hypertrophy. Morning urine albumin and creatinine were measured to calculate UACR. The patients were followed for 60±4 months and the composite end point (CEP) of cardiovascular (CV) death, nonfatal stroke or nonfatal myocardial infarction was recorded. The incidence of CEP increased with increasing LV mass (below the lower quartile of 194 g to above the upper quartile of 263 g) in patients with UACR below (6.7, 5.0, 9.1%) and above the median value of 1.406 mg/mmol (9.7, 17.0, 19.0%***). Also the incidence of CV death increased with LV mass in patients with UACR below (0, 1.4, 1.3%) and above 1.406 mg/mmol (2.2, 6.4, 8.0%**). The incidence of CEP was predicted by logUACR (hazard ratio (HR)=1.44** for every 10-fold increase in UACR) after adjustment for Framingham risk score (HR=1.05***), history of peripheral vascular disease (HR=2.3*) and cerebrovascular disease (HR=2.1*). LV mass did not enter the model. LogUACR predicted CV death (HR=2.4**) independently of LV mass (HR=1.01* per gram) after adjustment for Framingham risk score (HR=1.05*), history of diabetes mellitus (HR=2.4*) and cerebrovascular disease (HR=3.2*). *P<0.05, **P<0.01, ***P<0.001. In conclusion, UACR predicted CEP and CV death independently of LV mass. CV death was predicted by UACR and LV mass in an additive manner after adjustment for Framingham risk score and history of CV disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Liao Y et al. Prediction of mortality risk by different methods of indexation for left ventricular mass. J Am Coll Cardiol 1997; 29: 648–650, (see comments).
Borch-Johnsen K et al. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999; 19: 1992–1997.
Wachtell K et al. Are urinary albumin excretion and left ventricular hypertrophy both independent predictors of overall mortality in patients with electrocardiographic left ventricular hypertrophy? J Am Coll Cardiol 2002; 39: 237A.
Jensen JS, Borch-Johnsen K, Jensen G, Feldt-Rasmussen B . Atherosclerotic risk factors are increased in clinically healthy subjects with microalbuminuria. Atherosclerosis 1995; 112: 245–252.
Cirillo M et al. Microalbuminuria in nondiabetic adults: relation of blood pressure, body mass index, plasma cholesterol levels, and smoking: the Gubbio Population Study. Arch Intern Med 1998; 158: 1933–1939.
Jensen JS, Borch-Johnsen K, Jensen G, Feldt-Rasmussen B . Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subjects. Clin Sci (Colch) 1995; 88: 629–633.
Jensen JS . Renal and systemic transvascular albumin leakage in severe atherosclerosis. Arterioscler Thromb Vasc Biol 1995; 15: 1324–1329.
Olsen MH et al. Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. Am Heart J 2002; 144: 530–537.
Dahlof B et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study (in process citation). Hypertension 1998; 32: 989–997.
Wachtell K et al. Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population: the LIFE study. Hypertension 2000; 35(1 Part 1): 6–12.
Devereux RB et al. Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE Study. Blood Press 2001; 10: 74–82.
Sahn DJ, DeMaria A, Kisslo J, Weyman A . Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072–1083.
Schiller NB et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2: 358–367.
Palmieri V et al. Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement (see comments). J Am Coll Cardiol 1999; 34: 1625–1632.
Wachtell K et al. Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (The LIFE Study). Losartan Intervention For Endpoint. Am J Cardiol 2001; 87: 54–60.
Dubin J, Wallerson DC, Cody RJ, Devereux RB . Comparative accuracy of Doppler echocardiographic methods for clinical stroke volume determination. Am Heart J 1990; 120: 116–123.
de Simone G et al. Age-related changes in total arterial capacitance from birth to maturity in a normotensive population. Hypertension 1997; 29: 1213–1217.
de Simone G et al. Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. J Am Coll Cardiol 1994; 23: 1444–1451.
Devereux RB et al. Relation of left ventricular midwall function to cardiovascular risk factors and arterial structure and function. Hypertension 1998; 31: 929–936.
Roman MJ et al. Association of carotid atherosclerosis and left ventricular hypertrophy. J Am Coll Cardiol 1995; 25: 83–90.
Rowe DJ, Dawnay A, Watts GF . Microalbuminuria in diabetes mellitus: review and recommendations for the measurement of albumin in urine. Ann Clin Biochem 1990; 27(Part 4): 297–312.
Irgens-Moller L, Hemmingsen L, Holm J . Diagnostic value of microalbuminuria in pre-eclampsia. Clin Chim Acta 1986; 157: 295–298.
Jensen JS, Borch-Johnsen K, Feldt-Rasmussen BF, Jensen G . Screening of microalbuminuria with the Micral-test. A semi-quantitative urinary dipstick. Ugeskr Laeger 1993; 155: 4155–4157.
Borch-Johnsen K, Wenzel H, Viberti GC, Mogensen CE . Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes? BMJ 1993; 306: 1722–1725.
Feldt-Rasmussen B et al. Microalbuminuria: an important diagnostic tool. J Diabetes Complic 1994; 8: 137–145.
Jensen JS et al. Reduced glomerular size- and charge-selectivity in clinically healthy individuals with microalbuminuria. Eur J Clin Invest 1995; 25: 608–614.
Jensen JS et al. Microalbuminuria and its relation to cardiovascular disease and risk factors. A population-based study of 1254 hypertensive individuals. J Hum Hypertens 1997; 11: 727–732, (see comments).
Olsen MH et al. Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. Am Heart J 2002; 144: 530–537.
Roman MJ et al. Parallel cardiac and vascular adaptation in hypertension. Circulation 1992; 86: 1909–1918.
Jones EC et al. Relation of hemodynamic volume load to arterial and cardiac size. J Am Coll Cardiol 1997; 29: 1303–1310.
Vogt M, Motz W, Scheler S, Strauer BE . Disorders of coronary microcirculation and arrhythmias in systemic arterial hypertension. Am J Cardiol 1990; 65: 45G–50G.
Koren MJ et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345–352.
Acknowledgements
We thank Mary Paranicas, BA, Shonna Cohen, BA and Andreas Moan, MD, for their invaluable assistance with study coordination. Furthermore, we thank the LIFE echocardiography study investigators:
This work was supported in part by grants from Merck & Co., Inc., West Point, PA, USA.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Olsen, M., Wachtell, K., Bella, J. et al. Albuminuria predicts cardiovascular events independently of left ventricular mass in hypertension: a LIFE substudy. J Hum Hypertens 18, 453–459 (2004). https://doi.org/10.1038/sj.jhh.1001711
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1001711
Keywords
This article is cited by
-
New semiquantitative ultrasonographic score for peripheral arterial disease assessment and its association with cardiovascular risk factors
Hypertension Research (2016)
-
Investigating silent strokes in hypertensives: a magnetic resonance imaging study (ISSYS): rationale and protocol design
BMC Neurology (2013)
-
Blood pressure variability and multiple organ damage in primary hypertension
Journal of Human Hypertension (2013)
-
Urinary albumin excretion, even within the normal range, predicts an increase in left ventricular mass over the following 5 years
Kidney International (2010)
-
Risk Reduction After Regression of Echocardiographic Left Ventricular Hypertrophy in Hypertension: A Meta-Analysis
American Journal of Hypertension (2010)